AKT1 and prostate carcinoma: Thio-2, a novel compound derived from Thioflavin S, has been predicted to bind the BAG domain of BAG-1 isoforms though in silico docking experiments, and studies in melanoma, breast and prostate cancer cell lines, have suggested a reduction in binding of BAG-1 to its binding partners (such as HSC/P70, BRAF, and AR), to inhibit AR, MEK, and AKT signaling (15, 26, 53).